Symbol
| KDM6B
| contributors: mct/npt/pgu - updated : 08-02-2022
|
HGNC name
| lysine (K)-specific demethylase 6B
|
HGNC id
| 29012
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --over
|  
|
in esophageal squamous cell carcinoma (ESCC) patients with lymph node metastasis | tumoral
|  
|  
| --low
|  
|
in poorly differentiated high-risk neuroblastomas | tumoral
|  
|  
| --over
|  
|
in differentiated tumors, and high KDM6B expression is prognostic for better survival in neuroblastoma patients | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
| low KDM6B was an independent predictor of poor prognosis in surgically resected colorectal cancer (CRC) patients | Therapy target
|
System | Type | Disorder | Pubmed |
immunology | autoimmune | | |
KDM6B can be a novel therapeutic target for suppressing autoimmune responses | osteoarticular | bone | ostéoporosis | |
KDM6B may present as therapeutic targets for controlling mesenchymal stem/stromal cells (MSCs) fate choices and lead to clues for new treatment in metabolic bone diseases such as osteoporosis | cardiovascular | atheroma | | |
cell-specific pharmacologic therapy targeting KDM6B may be an effective intervention for Abdominal aortic aneurysms (AAAs) expansion | cancer | digestive | colon | |
potential new therapeutic targetapproach for CRC patients |
| | |
| Jmjd3-deficient mice were resistant to the induction of experimental autoimmune encephalomyelitis (EAE) |